口服选择性雌激素受体降解剂 Imlunestrant 作为单药或与阿柏西尼联合治疗复发性/晚期 ER 阳性子宫内膜样内膜癌:1a/1b期EMBER研究结果。

IF 4.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Gynecologic oncology Pub Date : 2024-10-22 DOI:10.1016/j.ygyno.2024.10.006
Kan Yonemori , Valentina Boni , Kim Gun Min , Tarek M. Meniawy , Janine Lombard , Peter A. Kaufman , Debra L. Richardson , Laura Bender , Meena Okera , Koji Matsumoto , Karthik V. Giridhar , José Angel García-Sáenz , Hans Prenen , Bernard Doger de Speville Uribe , Don S. Dizon , Javier Garcia-Corbacho , Els Van Nieuwenhuysen , Yujia Li , Shawn T. Estrem , Bastien Nguyen , Kalyan Banda
{"title":"口服选择性雌激素受体降解剂 Imlunestrant 作为单药或与阿柏西尼联合治疗复发性/晚期 ER 阳性子宫内膜样内膜癌:1a/1b期EMBER研究结果。","authors":"Kan Yonemori ,&nbsp;Valentina Boni ,&nbsp;Kim Gun Min ,&nbsp;Tarek M. Meniawy ,&nbsp;Janine Lombard ,&nbsp;Peter A. Kaufman ,&nbsp;Debra L. Richardson ,&nbsp;Laura Bender ,&nbsp;Meena Okera ,&nbsp;Koji Matsumoto ,&nbsp;Karthik V. Giridhar ,&nbsp;José Angel García-Sáenz ,&nbsp;Hans Prenen ,&nbsp;Bernard Doger de Speville Uribe ,&nbsp;Don S. Dizon ,&nbsp;Javier Garcia-Corbacho ,&nbsp;Els Van Nieuwenhuysen ,&nbsp;Yujia Li ,&nbsp;Shawn T. Estrem ,&nbsp;Bastien Nguyen ,&nbsp;Kalyan Banda","doi":"10.1016/j.ygyno.2024.10.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a phase 1a/b trial of imlunestrant, as monotherapy and combined with targeted therapy, in patients with ER+ advanced breast cancer or endometrioid endometrial cancer (EEC). This report focuses on patients with ER+ EEC.</div></div><div><h3>Methods</h3><div>EMBER used an i3 + 3 dose-escalation design to determine the recommended phase 2 dose (RP2D) followed by dose-expansion cohorts (1:1 randomization): imlunestrant monotherapy and imlunestrant plus abemaciclib (150 mg twice daily). Eligible patients had measurable disease and progression or recurrence after platinum-containing chemotherapy. Prior fulvestrant or aromatase inhibitor was not allowed. Secondary endpoints included safety, pharmacokinetics and antitumor activity.</div></div><div><h3>Results</h3><div>In total, 72 patients with a median of 2 prior anticancer therapies were treated. Among the 39 patients who received imlunestrant (400 mg [RP2D], <em>n</em> = 33; 800 mg, <em>n</em> = 6), the most common treatment-emergent adverse events (TEAEs) were grade 1–2 nausea (35.9 %), diarrhea (25.6 %), urinary tract infection (25.6 %), and abdominal pain (20.5 %). Overall response rate (ORR) was 10.3 %, clinical benefit rate (CBR) was 33.3 %, and median progression-free survival (mPFS) was 3.8 months (95 % CI, 1.8–6.7). Among the 33 patients who received imlunestrant (400 mg [RP2D], <em>n</em> = 29; 800 mg, <em>n</em> = 4) plus abemaciclib, the most common TEAEs were diarrhea (87.9 %), nausea (66.7 %), fatigue (48.5 %), and anemia (45.5 %). ORR was 18.2 %, CBR was 42.4 %, and mPFS was 6.8 months (95 % CI, 2.1–12).</div></div><div><h3>Conclusion</h3><div>Imlunestrant, as monotherapy and combined with abemaciclib, has a manageable safety profile with preliminary evidence of antitumor activity in patients with ER+ EEC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study\",\"authors\":\"Kan Yonemori ,&nbsp;Valentina Boni ,&nbsp;Kim Gun Min ,&nbsp;Tarek M. Meniawy ,&nbsp;Janine Lombard ,&nbsp;Peter A. Kaufman ,&nbsp;Debra L. Richardson ,&nbsp;Laura Bender ,&nbsp;Meena Okera ,&nbsp;Koji Matsumoto ,&nbsp;Karthik V. Giridhar ,&nbsp;José Angel García-Sáenz ,&nbsp;Hans Prenen ,&nbsp;Bernard Doger de Speville Uribe ,&nbsp;Don S. Dizon ,&nbsp;Javier Garcia-Corbacho ,&nbsp;Els Van Nieuwenhuysen ,&nbsp;Yujia Li ,&nbsp;Shawn T. Estrem ,&nbsp;Bastien Nguyen ,&nbsp;Kalyan Banda\",\"doi\":\"10.1016/j.ygyno.2024.10.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a phase 1a/b trial of imlunestrant, as monotherapy and combined with targeted therapy, in patients with ER+ advanced breast cancer or endometrioid endometrial cancer (EEC). This report focuses on patients with ER+ EEC.</div></div><div><h3>Methods</h3><div>EMBER used an i3 + 3 dose-escalation design to determine the recommended phase 2 dose (RP2D) followed by dose-expansion cohorts (1:1 randomization): imlunestrant monotherapy and imlunestrant plus abemaciclib (150 mg twice daily). Eligible patients had measurable disease and progression or recurrence after platinum-containing chemotherapy. Prior fulvestrant or aromatase inhibitor was not allowed. Secondary endpoints included safety, pharmacokinetics and antitumor activity.</div></div><div><h3>Results</h3><div>In total, 72 patients with a median of 2 prior anticancer therapies were treated. Among the 39 patients who received imlunestrant (400 mg [RP2D], <em>n</em> = 33; 800 mg, <em>n</em> = 6), the most common treatment-emergent adverse events (TEAEs) were grade 1–2 nausea (35.9 %), diarrhea (25.6 %), urinary tract infection (25.6 %), and abdominal pain (20.5 %). Overall response rate (ORR) was 10.3 %, clinical benefit rate (CBR) was 33.3 %, and median progression-free survival (mPFS) was 3.8 months (95 % CI, 1.8–6.7). Among the 33 patients who received imlunestrant (400 mg [RP2D], <em>n</em> = 29; 800 mg, <em>n</em> = 4) plus abemaciclib, the most common TEAEs were diarrhea (87.9 %), nausea (66.7 %), fatigue (48.5 %), and anemia (45.5 %). ORR was 18.2 %, CBR was 42.4 %, and mPFS was 6.8 months (95 % CI, 2.1–12).</div></div><div><h3>Conclusion</h3><div>Imlunestrant, as monotherapy and combined with abemaciclib, has a manageable safety profile with preliminary evidence of antitumor activity in patients with ER+ EEC.</div></div>\",\"PeriodicalId\":12853,\"journal\":{\"name\":\"Gynecologic oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologic oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0090825824011569\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825824011569","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:依仑司群是一种新一代口服选择性雌激素受体降解剂,旨在提供持续的雌激素受体(ER)靶点抑制。EMBER是一项1a/b期试验,对ER+晚期乳腺癌或子宫内膜样内膜癌(EEC)患者进行伊莫司群单药或联合靶向治疗。本报告主要针对ER+ EEC患者:EMBER采用i3 + 3剂量递增设计来确定推荐的2期剂量(RP2D),然后进行剂量扩展队列(1:1随机化):imlunestrant单药治疗和imlunestrant加abemaciclib(150毫克,每天两次)。符合条件的患者在接受含铂化疗后病情进展或复发。不允许使用氟维司群或芳香化酶抑制剂。次要终点包括安全性、药代动力学和抗肿瘤活性:共有72名患者接受了治疗,其中中位数患者曾接受过2次抗癌治疗。在接受依仑司群(400 毫克 [RP2D],n = 33;800 毫克,n = 6)治疗的 39 名患者中,最常见的治疗突发不良事件(TEAEs)为 1-2 级恶心(35.9%)、腹泻(25.6%)、尿路感染(25.6%)和腹痛(20.5%)。总体反应率(ORR)为 10.3%,临床获益率(CBR)为 33.3%,中位无进展生存期(mPFS)为 3.8 个月(95% CI,1.8-6.7)。在接受依仑司坦(400 毫克 [RP2D],n = 29;800 毫克,n = 4)加阿培莫司利治疗的 33 例患者中,最常见的 TEAE 为腹泻(87.9%)、恶心(66.7%)、疲劳(48.5%)和贫血(45.5%)。ORR为18.2%,CBR为42.4%,mPFS为6.8个月(95% CI,2.1-12):结论:Imlunestrant作为单药或与abemaciclib联合用药,在ER+ EEC患者中具有可控的安全性和初步的抗肿瘤活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study

Objective

Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a phase 1a/b trial of imlunestrant, as monotherapy and combined with targeted therapy, in patients with ER+ advanced breast cancer or endometrioid endometrial cancer (EEC). This report focuses on patients with ER+ EEC.

Methods

EMBER used an i3 + 3 dose-escalation design to determine the recommended phase 2 dose (RP2D) followed by dose-expansion cohorts (1:1 randomization): imlunestrant monotherapy and imlunestrant plus abemaciclib (150 mg twice daily). Eligible patients had measurable disease and progression or recurrence after platinum-containing chemotherapy. Prior fulvestrant or aromatase inhibitor was not allowed. Secondary endpoints included safety, pharmacokinetics and antitumor activity.

Results

In total, 72 patients with a median of 2 prior anticancer therapies were treated. Among the 39 patients who received imlunestrant (400 mg [RP2D], n = 33; 800 mg, n = 6), the most common treatment-emergent adverse events (TEAEs) were grade 1–2 nausea (35.9 %), diarrhea (25.6 %), urinary tract infection (25.6 %), and abdominal pain (20.5 %). Overall response rate (ORR) was 10.3 %, clinical benefit rate (CBR) was 33.3 %, and median progression-free survival (mPFS) was 3.8 months (95 % CI, 1.8–6.7). Among the 33 patients who received imlunestrant (400 mg [RP2D], n = 29; 800 mg, n = 4) plus abemaciclib, the most common TEAEs were diarrhea (87.9 %), nausea (66.7 %), fatigue (48.5 %), and anemia (45.5 %). ORR was 18.2 %, CBR was 42.4 %, and mPFS was 6.8 months (95 % CI, 2.1–12).

Conclusion

Imlunestrant, as monotherapy and combined with abemaciclib, has a manageable safety profile with preliminary evidence of antitumor activity in patients with ER+ EEC.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
期刊最新文献
Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months KRAS mutations in endometrial cancers: Possible prognostic and treatment implications Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years Disparities in ovarian cancer survival among ethnic Asian American populations, 2006–2020
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1